Public Employees Retirement Association of Colorado Has $22.35 Million Stake in Pfizer Inc. (NYSE:PFE)

Public Employees Retirement Association of Colorado lowered its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 805,304 shares of the biopharmaceutical company’s stock after selling 39,006 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Pfizer were worth $22,347,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of PFE. Advisor OS LLC lifted its stake in Pfizer by 1.0% in the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after buying an additional 365 shares in the last quarter. Safeguard Investment Advisory Group LLC raised its stake in shares of Pfizer by 3.9% in the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 371 shares during the period. Lantz Financial LLC lifted its holdings in shares of Pfizer by 1.3% in the first quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock valued at $849,000 after purchasing an additional 381 shares in the last quarter. Wellington Shields Capital Management LLC grew its holdings in shares of Pfizer by 1.3% during the first quarter. Wellington Shields Capital Management LLC now owns 30,750 shares of the biopharmaceutical company’s stock worth $853,000 after buying an additional 385 shares in the last quarter. Finally, King Wealth Management Group raised its position in Pfizer by 2.4% in the 4th quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock valued at $480,000 after buying an additional 388 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PFE. Morgan Stanley raised their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday, July 10th. Barclays raised their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 10th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $34.50.

Pfizer Stock Performance

PFE traded up $0.06 during trading on Monday, hitting $30.83. The stock had a trading volume of 24,510,881 shares, compared to its average volume of 39,623,016. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The company has a 50 day moving average price of $28.54 and a 200-day moving average price of $27.75. Pfizer Inc. has a one year low of $25.20 and a one year high of $37.19. The firm has a market cap of $174.70 billion, a price-to-earnings ratio of -508.75, a P/E/G ratio of 1.20 and a beta of 0.69.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the previous year, the business posted $1.23 earnings per share. Pfizer’s quarterly revenue was down 19.5% on a year-over-year basis. As a group, research analysts predict that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.45%. Pfizer’s dividend payout ratio is presently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.